Maze Therapeutics, Inc.
No enriched coverage for $MAZE in the last 7 days.
Courtney Phillips (GC and Corp. Secretary) sold 3,993 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.10M total) across 4 trades over 2026-09-02 to 2026-09-03.
Dandekar Atul (CSBO) sold 6,434 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.81–$27.12, $0.17M total) across 4 trades over 2026-09-02 to 2026-09-03.
Coloma Jason V (Chief Executive Officer) sold 22,638 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.77–$27.12, $0.59M total) across 4 trades over 2026-09-02 to 2026-09-03.
Recent MAZE coverage spans insider activity, corporate actions and earnings.
In the last 30 days, MAZE insiders filed 21 SEC Form 4 transactions — no purchases and 21 sales ($3.1M). The most active reporter was Bernstein Harold, President, R&D & CMO, with 6 filings. 24% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor insider sell may signal slight negative sentiment but unlikely to move price materially.
Insider sale may signal lack of confidence, potentially pressuring the stock short-term.
Insider sell may signal lack of confidence, adding short-term sell pressure.
Insider sale may signal reduced confidence or portfolio rebalancing.
The insider sale may pressure the stock short term as the CEO reduces his holding.
alphai scores every news story that mentions MAZE with an AI model for sentiment and relevance, and aggregates insider trades from Maze Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Courtney Phillips (GC and Corp. Secretary) sold 3,993 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.10M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readDandekar Atul (CSBO) sold 6,434 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.81–$27.12, $0.17M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readColoma Jason V (Chief Executive Officer) sold 22,638 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.77–$27.12, $0.59M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readBernstein Harold (President, R&D & CMO) sold 10,295 shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.24 ($25.78–$27.12, $0.27M total) across 4 trades over 2026-09-02 to 2026-09-03.
1 min readColoma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.29 ($26.29–$26.31, $0.91M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.
1 min readMaze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Maze Therapeutics Announces Appointments to Its Board of Directors August 13, 2026 Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FR
2 min readMaze Therapeutics, Inc. (MAZE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Enrollment in Phase 2 HORIZON trial of MZE829 on track; data from all cohorts expected in late 2026 or early 2027 Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongo
4 min readColoma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $26.73 ($26.71–$27.09, $0.92M total) across 4 trades on 2026-08-03 under a Rule 10b5-1 trading plan.
1 min readMaze Therapeutics said Phase 2 HORIZON topline results for MZE829 in APOL1-mediated kidney disease were positive, and its MZE782 program continues toward Phase 2 in PKU and CKD. It also began the Phase 2 ESPRIT trial for partnered S-606001, leading to a $20 million milestone payment from Shionogi. MAZE is a clinical-stage biotech with no FDA-approved AMKD therapies.
2 min readColoma Jason V (Chief Executive Officer) sold 34,501 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at an average of $29.98 ($29.95–$30.44, $1.03M total) across 3 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
2 min read